Pharmaniaga's financials are still messy with that massive PN17 hit, and until their balance sheet clears up, the fundamentals remain very shaky for long-term holding. 18-19 cents is just a psychological resistance; until they actually show sustainable profit growth, better to wait on the sidelines.

Pharma is very potential stock base on 2 important reasons:- 1.Production of human insulin contracts at its Puchong plant is scaling up. This moves the company away from being just a low-margin logistical middleman to a high-margin manufacturer. 2.Analysts estimate that Pharmaniaga could pay out 50% to 70% of its net profit as dividends. This is a major catalyst that will draw back large institutional funds.